US investors race to license China biotech
US investors are rushing to license drugs from China as the country’s biotech sector gains global clout. Nearly 30% of recent pharmaceutical licensing deals involved Chinese firms, up sharply from prior years. VCs cite competitive pricing, speed, and innovation, with companies like Pfizer and Verdiva already securing major deals.